PROTAC Nanomedicine Destroys Cancer Protein to Trigger Cell Death via Ferroptosis

This groundbreaking study introduces a novel nanomedicine that exploits cancer cells' dependence on lipid metabolism to trigger their destruction. Researchers developed PRO-P, a 170-nanometer nanoparticle that combines a protein-degrading molecule (PROTAC) with a light-activated photosensitizer.

The team studied triple-negative breast cancer (TNBC), an aggressive form with limited treatment options. They targeted HMGCR, the rate-limiting enzyme in cholesterol synthesis that cancer cells rely on for survival. Unlike statins that temporarily block this enzyme, their PROTAC permanently destroys it, preventing cancer cells from rebuilding their defenses.

In laboratory studies using 4T1 breast cancer cells, PRO-P increased cellular uptake by 1.34-fold and elevated toxic reactive oxygen species by 9.5-fold when activated by laser light. The treatment forced cancer cells into ferroptosis, a form of programmed cell death driven by iron-dependent lipid damage.

Animal studies revealed remarkable efficacy: a single treatment with laser activation achieved 92.5% tumor regression and completely eliminated lung metastases. Importantly, the treatment showed no systemic toxicity. Immune analysis revealed profound microenvironment remodeling, with 2.6-fold more cancer-killing CD8+ T cells, 4.3-fold more mature dendritic cells, and fewer immunosuppressive regulatory T cells.

This approach represents a paradigm shift from traditional cancer therapy. By permanently disrupting cancer metabolism rather than temporarily blocking it, the treatment overcomes resistance mechanisms while precisely targeting tumors through light activation. The dual mechanism—metabolic disruption plus immune activation—creates durable anti-cancer memory that could prevent recurrence.